103 related articles for article (PubMed ID: 3415713)
21. Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys.
Liu XW; Song HF; Tang ZM; Zhao K; Zhu BZ; Wang LP; Zhang Y
Acta Pharmacol Sin; 2002 Sep; 23(9):842-6. PubMed ID: 12230955
[TBL] [Abstract][Full Text] [Related]
22. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
[TBL] [Abstract][Full Text] [Related]
23. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes.
Liu Y; Lu WL; Zhang X; Wang XQ; Zhang H; Zhang Q
Peptides; 2005 Mar; 26(3):423-30. PubMed ID: 15652649
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans.
Angst MS; Dyck JB; Azarnoff DL; Goldblum R; Ho B; Gfroerer T; Linton EA; Glynn BP; Shafer SL
Clin Pharmacol Ther; 1998 Nov; 64(5):499-510. PubMed ID: 9834042
[TBL] [Abstract][Full Text] [Related]
26. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
27. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans.
Schran HF; Tse FL
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):1-4. PubMed ID: 3988387
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
31. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
32. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
[TBL] [Abstract][Full Text] [Related]
33. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
[TBL] [Abstract][Full Text] [Related]
34. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of 125I-hirudin in rats and dogs.
Richter M; Cyranka U; Nowak G; Walsmann P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):64-9. PubMed ID: 2459034
[TBL] [Abstract][Full Text] [Related]
36. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK
Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
[TBL] [Abstract][Full Text] [Related]
37. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
[TBL] [Abstract][Full Text] [Related]
39. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers.
Pentikäinen PJ; Neuvonen PJ; Penttilä A
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):98-107. PubMed ID: 6341263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
